Results 171 to 180 of about 33,788 (287)

Beyond barriers: when neurons act immune and immunity acts neural. [PDF]

Signal Transduct Target Ther
Kim SW, Seok SH.
europepmc   +1 more source

Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed

European Journal of Neurology, Volume 33, Issue 3, March 2026.
This post hoc analysis of data from the DELIVER trial evaluated long‐term maintenance of early ≥ 50% and ≥ 75% migraine response. For both eptinezumab doses (100 or 300 mg), ≥ 50% or ≥ 75% migraine response over Weeks 1–12 or 1–24 was maintained for the entire 72‐week treatment period for many participants.
Jessica Ailani, Messoud Ashina, Susanne F. Awad, Xin Ying Lee, Line Pickering Boserup, Seema Soni‐Brahmbhatt, Bjørn Sperling, Richard B. Lipton   +7 more
wiley   +1 more source

Permanent visual impairment following a Behçet's disease flare while on calcitonin gene-related peptide receptor antagonist therapy: a case report. [PDF]

BMC Ophthalmol
Khan FA, Malik A, Nelson E, Fahimdanesh K, Kaur K, Elison J, Sayed M.   +6 more
europepmc   +1 more source

Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 584-594, March 2026.
Plain Language Summary While migraine headaches can be hard to predict, some patients believe headaches are connected to the moon‘s phases. Our research showed that migraine attacks were 34% more likely to occur during the new moon than during the full moon.
Alexander Yoo, Brendan Keenan, Angeliki Vgontzas, Murray A. Mittleman, Suzanne M. Bertisch, Ron Anafi   +5 more
wiley   +1 more source

Gepants: targeting the CGRP pathway for migraine relief. [PDF]

Front Pharmacol
Jakubowska B, Sowa-Kućma M.
europepmc   +1 more source

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 604-614, March 2026.
Abstract Objective This study assesses the 3‐month effectiveness of the calcitonin gene‐related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications. Background Studies comparing the effectiveness of calcitonin gene‐related peptide monoclonal antibodies versus traditional oral migraine preventive medications ...
Richard B. Lipton, Miguel J. A. Láinez, Zubair Ahmed, Carlos Vallarino, Diego Novick, Maurice Vincent, Lars Viktrup, Rebecca L. Robinson   +7 more
wiley   +1 more source

The Neuroimmune Axis in Gastric Cancer: Bridging Neural Regulation, Tumor Microenvironment, and Immunotherapy. [PDF]

Oncol Res
Zhang F, Wang X, Shen X, Xiong P, Yang Y, Wang J.   +5 more
europepmc   +1 more source

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 658-671, March 2026.
Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima, Renata Rao, Gyöngyi Szabó, Sebastian Szklener, Cristina Tassorelli, Marcin Nastaj, Denise E. Chou, Ani C. Khodavirdi, Mahan Chehrenama, Yineng Zhu, Ajay K. Bhatia, David W. Dodick   +11 more
wiley   +1 more source

Brain-Region-Mediated Neuroimmune Modulation in Sepsis: Research Advances and Therapeutic Prospects. [PDF]

J Inflamm Res
Zhou X, Tang Y, Chen H, Huang W, Qiu H.
europepmc   +1 more source

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 672-687, March 2026.
Abstract Background The transient receptor potential melastatin 3 (TRPM3) ion channel has been implicated in sensory modulation and pain transmission and may contribute to migraine pathophysiology through calcitonin gene‐related peptide (CGRP) release in the trigeminovascular system. This study aimed to investigate TRPM3 activation and its role in CGRP
Philip V. Reducha, Lukas K. S. Nielsen, Mette N. Jensen, Jacob C. A. Edvinsson, Spyridoula Kazantzi, Sofia L. Wæver, Tanja Lylloff, Connar S. J. Westgate, Lars Edvinsson, Kristian A. Haanes   +9 more
wiley   +1 more source